GHRP-2
A growth hormone secretagogue that appears in older GH-optimization discussions and research-market listings.
Also appears in: Muscle Growth
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary lane: Growth Hormone. Also surfaces under Muscle Growth for browsing and discovery.
No major aliases are tracked for this profile yet.
No FDA label signal · 0 trials · 204 PubMed results
Current evidence for GHRP-2 is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
GHRP-2 has no clinical trials that name it and 204 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What GHRP-2 is
GHRP-2 is one of the older growth hormone secretagogues that helped define the GH-focused peptide niche before the current metabolic-drug wave took over most attention.
Why it matters
It provides context for how the peptide market evolved. Many modern GH stacks and blends still reference earlier secretagogue-era compounds like GHRP-2.
Regulatory context
GHRP-2 is not an FDA-approved GH optimization treatment in the United States and should be read as a research-market profile.
Practical reading note
When comparing GH-related peptides, it helps to distinguish between branded medical therapies, diagnostic tools, and research-market secretagogues.